OncoCyte (NAS:OCX) Net Cash per Share

: $-0.40 (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

Net cash per share is calculated as Cash And Cash Equivalents minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). OncoCyte's net cash per share for the quarter that ended in Sep. 2022 was $-0.40.

The historical rank and industry rank for OncoCyte's Net Cash per Share or its related term are showing as below:

During the past 9 years, the highest Price-to-Net-Cash Ratio of OncoCyte was 58.13. The lowest was 0.00. And the median was 18.87.

OncoCyte Net Cash per Share Historical Data

The historical data trend for OncoCyte's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Cash per Share

0.08

0.06

0.24

-0.20

-0.63

OncoCyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Cash per Share																-0.27	-0.63	-0.74	-0.32	-0.40

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Net Cash per Share, along with its competitors' market caps and Net Cash per Share data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

OncoCyte Net Cash per Share Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Net Cash per Share distribution charts can be found below:

* The bar in red indicates where OncoCyte's Net Cash per Share falls in comparison to its industry or sector. The grey bar indicates the Net Cash per Share's extreme value range as defined by GuruFocus.

OncoCyte Net Cash per Share Calculation

In the calculation of a company's net cash, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative net cash. But sometimes a company's price may be lower than its net-cash.

OncoCyte's Net Cash Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Net Cash Per Share (A: Dec. 2021 )	=	(Cash And Cash Equivalents^**	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
	=	(36.509	-	94.346	-	0)	/	92.2319
	=	-0.63

OncoCyte's Net Cash Per Share for the quarter that ended in Sep. 2022 is calculated as

Net Cash Per Share (Q: Sep. 2022 )	=	(Cash And Cash Equivalents^**	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
	=	(32.472	-	80.487	-	0)	/	118.619
	=	-0.40

** Note that the Cash And Cash Equivalents here include cash, cash equivalents and short-term investments.

OncoCyte (NAS:OCX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener. GuruFocus also publishes a monthly Net-Net newsletter.

OncoCyte Net Cash per Share Related Terms

Thank you for viewing the detailed overview of OncoCyte's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (NAS:OCX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoCyte Corp (NAS:OCX) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

7OC:Germany

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Executives

Josh Riggs	officer: Interim CEO	15 CUSHING, IRVINE CA 92618
Lou Silverman	director
James Yang Liu	officer: Controller, PAO	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund	director	C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John	officer: SVP, Finance, and Interim CFO	C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc	10 percent owner	512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen	10 percent owner	C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen	officer: Chief Operating Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu	officer: VP Cntrllr/Prncpl Acctng Offcr	120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter	director	C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross	officer: Chief Medical Officer	15 CUSHING, IRVINE CA 92618
Tony T Kalajian	officer: SVP-Chief Accounting Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith	director	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar	officer: SVP, Marketing & Market Access	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews	director	5791 VAN ALLEN WAY, CARLSBAD CA 92008